According to the latest report by IMARC Group, titled “Antihypertensive Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” the global antihypertensive drugs market size reached US$ 28.7 Billion in 2022. Antihypertensive drugs, also known as antihypertensives, are medications used to treat high blood pressure, a condition known as hypertension. Hypertension is a chronic condition characterized by consistently elevated blood pressure levels, which can lead to significant health complications if left untreated. Antihypertensive drugs can be used alone or in combination to achieve optimal blood pressure control. They are effective in managing hypertension, along with lifestyle modifications, such as adopting a healthy diet, regular exercise, weight management, and stress reduction, are also crucial for long-term control of blood pressure. Regular monitoring and follow-up visits with healthcare professionals are necessary to assess the effectiveness of the medication and make any necessary adjustments to the treatment plan. Antihypertensive drugs work by targeting various mechanisms in the body to reduce blood pressure and help manage the condition. There are several classes of antihypertensive drugs available, each with its unique mode of action. These classes include diuretics, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), calcium channel blockers, and renin inhibitors. These medications are prescribed based on factors, such as the severity of hypertension, individual patient characteristics, and the presence of other health conditions.
Global Antihypertensive Drugs Market Trends:
The increasing screening programs and early detection of hypertension represents one of the significant factors driving the growth of the market across the globe. This is primarily attributed to the rising awareness regarding hypertension and its potential health risks, which is driving the market growth. The market is also driven by the rising incidences of hypertension due to sedentary lifestyles, poor dietary choices, and high-stress levels. Apart from this, the increasing number of cases of diabetes, kidney diseases, obstructive sleep apnea, and other cardiovascular diseases, which are widely considered as the primary causes of hypertension, is driving the growth of the market. In line with this, the steadily expanding geriatric population base is further contributing to the growth of the market. In addition to this, the expiration of patents for specific antihypertensive drugs has led to the introduction of generic versions, resulting in increased market competition and affordability, thereby facilitating the growth of the market. Other factors, including advancements in medical technology and drug delivery systems improving the effectiveness and convenience of antihypertensive treatments, and governments and healthcare organizations in several countries across the world implementing various initiatives to combat hypertension and reduce the associated disease burden, such as awareness campaigns, public health programs, and subsidies or reimbursement policies, are creating a positive outlook for the market across the globe. Looking forward, the market value is projected to reach US$ 34.9 Billion by 2028, expanding at a CAGR of 3.1% during 2023-2028.
- Based on therapeutic class, the market has been segmented into diuretics, ACE inhibitors, calcium channel blockers, beta-adrenergic blockers, vasodilators, and others. Currently, calcium channel blockers holds the largest market share worldwide.
- On the basis of the type, the market has been segregated into primary hypertension and secondary hypertension. Currently, primary hypertension accounted for the largest market share.
- Based on the distribution channel, the market has been classified into retail pharmacy, hospital pharmacy, and e-commerce. Presently, hospital pharmacy is holding the largest market share worldwide.
- On a geographical front, the market has been segmented into Asia Pacific, North America, Europe, Middle East and Africa, and Latin America. Presently, North America is dominating the market across the world.
- The competitive landscape of the market has also been examined with some of the key players being AstraZeneca, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Johnson & Johnson Services Inc., Lupin Pharmaceuticals Inc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi and Sun Pharmaceutical Industries Ltd.
|Base Year of the Analysis
||Therapeutic Class, Type, Distribution Channel, Region
||Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||AstraZeneca, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Johnson & Johnson Services Inc., Lupin Pharmaceuticals Inc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi and Sun Pharmaceutical Industries Ltd.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800